NCT05522894View on ClinicalTrials.gov

AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC

PHASE2UnknownINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 1, 2022

Primary Completion Date

April 1, 2024

Study Completion Date

October 1, 2024

Conditions
Unresectable Esophageal Squamous Cell CarcinomaLocally Advanced Esophageal Squamous Cell CarcinomaMetastatic Esophageal Squamous Cell Carcinoma
Interventions
DRUG

AK104

10mg/kg IV every 3 weeks (Q3W)

DRUG

Cisplatin

75mg/m2 IV every 3 weeks (Q3W)

DRUG

Paclitaxel

175mg/m2 IV every 3 weeks (Q3W)

Sponsors
All Listed Sponsors
collaborator

Akeso Pharmaceuticals, Inc.

OTHER

lead

Chinese Academy of Medical Sciences

OTHER